71 related articles for article (PubMed ID: 26107610)
1. Examining Ligand-Based Stabilization of Proteins in Cells with MEK1 Kinase Inhibitors.
Auld DS; Davis CA; Jimenez M; Knight S; Orme JP
Assay Drug Dev Technol; 2015 Jun; 13(5):266-76. PubMed ID: 26107610
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of cobalt(II)-Schiff base complexes as ATP-noncompetitive MEK1 inhibitors.
Li H; Xi D; Niu Y; Wang C; Xu F; Liang L; Xu P
J Inorg Biochem; 2019 Jun; 195():174-181. PubMed ID: 30954694
[TBL] [Abstract][Full Text] [Related]
4. MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.
Wu PK; Park JI
Semin Oncol; 2015 Dec; 42(6):849-62. PubMed ID: 26615130
[TBL] [Abstract][Full Text] [Related]
5. Detection of allosteric kinase inhibitors by displacement of active site probes.
Lebakken CS; Reichling LJ; Ellefson JM; Riddle SM
J Biomol Screen; 2012 Jul; 17(6):813-21. PubMed ID: 22453235
[TBL] [Abstract][Full Text] [Related]
6. U0126, a mitogen-activated protein kinase kinase 1 and 2 (MEK1 and 2) inhibitor, selectively up-regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells.
Smutny T; Bitman M; Urban M; Dubecka M; Vrzal R; Dvorak Z; Pavek P
Arch Toxicol; 2014 Dec; 88(12):2243-59. PubMed ID: 24819614
[TBL] [Abstract][Full Text] [Related]
7. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.
Ohren JF; Chen H; Pavlovsky A; Whitehead C; Zhang E; Kuffa P; Yan C; McConnell P; Spessard C; Banotai C; Mueller WT; Delaney A; Omer C; Sebolt-Leopold J; Dudley DT; Leung IK; Flamme C; Warmus J; Kaufman M; Barrett S; Tecle H; Hasemann CA
Nat Struct Mol Biol; 2004 Dec; 11(12):1192-7. PubMed ID: 15543157
[TBL] [Abstract][Full Text] [Related]
8. Substituted 3-benzylcoumarins as allosteric MEK1 inhibitors: design, synthesis and biological evaluation as antiviral agents.
Wang C; Zhang H; Xu F; Niu Y; Wu Y; Wang X; Peng Y; Sun J; Liang L; Xu P
Molecules; 2013 May; 18(5):6057-91. PubMed ID: 23698055
[TBL] [Abstract][Full Text] [Related]
9. Enzyme kinetics and binding studies on inhibitors of MEK protein kinase.
VanScyoc WS; Holdgate GA; Sullivan JE; Ward WH
Biochemistry; 2008 Apr; 47(17):5017-27. PubMed ID: 18393446
[TBL] [Abstract][Full Text] [Related]
10. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors.
Han S; Zhou V; Pan S; Liu Y; Hornsby M; McMullan D; Klock HE; Haugen J; Lesley SA; Gray N; Caldwell J; Gu XJ
Bioorg Med Chem Lett; 2005 Dec; 15(24):5467-73. PubMed ID: 16199156
[TBL] [Abstract][Full Text] [Related]
11. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation.
Wang H; Daouti S; Li WH; Wen Y; Rizzo C; Higgins B; Packman K; Rosen N; Boylan JF; Heimbrook D; Niu H
Cancer Res; 2011 Aug; 71(16):5535-45. PubMed ID: 21705440
[TBL] [Abstract][Full Text] [Related]
12. In silico investigation of new binding pocket for mitogen activated kinase kinase (MEK): Development of new promising inhibitors.
Yari H; Ganjalikhany MR; Sadegh H
Comput Biol Chem; 2015 Dec; 59 Pt A():185-98. PubMed ID: 26580563
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.
Daouti S; Wang H; Li WH; Higgins B; Kolinsky K; Packman K; Specian A; Kong N; Huby N; Wen Y; Xiang Q; Podlaski FJ; He Y; Fotouhi N; Heimbrook D; Niu H
Cancer Res; 2009 Mar; 69(5):1924-32. PubMed ID: 19244124
[TBL] [Abstract][Full Text] [Related]
14. Thermodynamics of nucleotide and non-ATP-competitive inhibitor binding to MEK1 by circular dichroism and isothermal titration calorimetry.
Smith CK; Windsor WT
Biochemistry; 2007 Feb; 46(5):1358-67. PubMed ID: 17260965
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a cobalt complex with high MEK1 binding affinity.
Li H; Zhou T; Liu H; Xu F; Niu Y; Wang C; Liang L; Xu P
Bioorg Med Chem Lett; 2017 May; 27(10):2221-2224. PubMed ID: 28385507
[TBL] [Abstract][Full Text] [Related]
16. 4-Anilino-7-alkenylquinoline-3-carbonitriles as potent MEK1 kinase inhibitors.
Berger DM; Dutia M; Powell D; Floyd MB; Torres N; Mallon R; Wojciechowicz D; Kim S; Feldberg L; Collins K; Chaudhary I
Bioorg Med Chem; 2008 Oct; 16(20):9202-11. PubMed ID: 18815050
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Inactive Conformation-Selective Kinase Inhibitors by Utilizing Cascade Assays.
Wang W; Krosky D; Ahn K
Biochemistry; 2017 Aug; 56(34):4449-4456. PubMed ID: 28574701
[TBL] [Abstract][Full Text] [Related]
18. Computational targeting of allosteric site of MEK1 by quinoline-based molecules.
Singh R; Bhardwaj VK; Purohit R
Cell Biochem Funct; 2022 Jul; 40(5):481-490. PubMed ID: 35604288
[TBL] [Abstract][Full Text] [Related]
19. MEK1/2 inhibitors reverse acute vascular occlusion in mouse models of sickle cell disease.
Zhao Y; Schwartz EA; Palmer GM; Zennadi R
FASEB J; 2016 Mar; 30(3):1171-86. PubMed ID: 26631480
[TBL] [Abstract][Full Text] [Related]
20. A selective cellular screening assay for B-Raf and c-Raf kinases.
Ish T; Sootome H; Yagi Y; Yamashita K; Noumi T; Noro N; Ishii T
J Biomol Screen; 2007 Sep; 12(6):818-27. PubMed ID: 17517901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
